Compare FXNC & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | CATX |
|---|---|---|
| Founded | 1907 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.4M | 262.5M |
| IPO Year | 2012 | 2018 |
| Metric | FXNC | CATX |
|---|---|---|
| Price | $30.45 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $33.00 | $10.57 |
| AVG Volume (30 Days) | 14.8K | ★ 3.4M |
| Earning Date | 10-23-2026 | 11-20-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 96.00 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $4.62 | $5.20 |
| P/E Ratio | $25.84 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $23.05 | $0.78 |
| 52 Week High | $33.24 | $6.16 |
| Indicator | FXNC | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 19.50 |
| Support Level | $30.47 | N/A |
| Resistance Level | $30.75 | $2.40 |
| Average True Range (ATR) | 1.00 | 0.20 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 52.11 | 2.45 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.